The FINANCIAL — Trulicity 1.5 mg and 0.75 mg provided superior hemoglobin A1c (A1C) reduction compared to Lantus in a study of patients with type 2 diabetes and primarily enrolled from East Asia, according to new data presented by Eli Lilly and Company. The head-to-head study was presented on June 8 at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.
“Continuing to research our medicines beyond the initial clinical trial program is important for patients and for the ongoing study of diabetes,” said Brad Woodward, M.D., senior medical director, Lilly Diabetes. “These results reinforce the value, safety and efficacy of once-weekly Trulicity for people in need of additional treatment when diet, exercise and oral medicines are not enough to give them the blood sugar control they need.”
After 26 weeks, both doses of Trulicity were superior to Lantus in A1C reduction, and significantly more patients reached the recommended A1C target of less than 7 percent, according to Lilly.
A1C reductions from baseline: -1.7 percent (Trulicity 1.5 mg), -1.32 percent (Trulicity 0.75 mg), -1.15 percent (Lantus).
Percentages of patients reaching target A1C levels ( < 7 percent): 65 percent (Trulicity 1.5 mg), 54 percent (Trulicity 0.75 mg), 41 percent (Lantus).1
Patients treated with Trulicity 1.5 mg and 0.75 mg also lost an average of 1.51 kg and 0.88 kg respectively, while patients treated with Lantus gained 0.96 kg.
Trulicity was well-tolerated in the study, showing fewer reports of hypoglycemia in patients treated with Trulicity 1.5 mg and 0.75 mg compared to Lantus. No severe hypoglycemia was reported. Other adverse events were gastrointestinal in nature, with more Trulicity-treated patients experiencing diarrhea (15.2 percent [Trulicity 1.5 mg], 8.4 percent [Trulicity 0.75 mg]) and nausea (8.7 percent [Trulicity 1.5 mg], 4.9 percent [Trulicity 0.75 mg]) compared to Lantus (1.6 percent [diarrhea] and 0.8 percent [nausea]). These results were consistent with previous Trulicity studies.1
Trulicity was approved by the U.S. Food and Drug Administration (FDA) in September 2014, and launched in the U.S. in November 2014. The European Commission granted marketing authorisation for Trulicity in November 2014, and launches are ongoing in the various countries. Additional regulatory applications are pending around the world.
Discussion about this post